Human Prealbumin (Transthyretin, TTR) ELISA Kit (with Control)

TTR) ELISA Kit (with Control)

• No Link Provided
• No Publication Provided
• No Snippet Provided

* Lee K et al. (2022) The Relationship of Plasma Transthyretin Level with Global or Regional Amyloid Beta Burden in Subjects with Amnestic Mild Cognitive Impairment: Cross-Sectional Amyloid PET Study. Psychiatry Clin Psychopharmacol.32(1):4-8.

• https://pmc.ncbi.nlm.nih.gov/articles/PMC11099618/pdf/pcp-32-1-4.pdf

* Ando Y et al. (2017) siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis. United States patent application: 20170096663 A1

• http://www.freepatentsonline.com/y2017/0096663.html

* Pasella S (2016) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 28(1):77-82.

• https://pubmed.ncbi.nlm.nih.gov/25995168/#affiliation-1

* Kallanthottathil R et al. (2016) RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES. Patent: US9399775 B2, PCT/US2012/065691.

• http://www.google.com.do/patents/US9399775

* Chai Y et al. (2015) Identification of biomarkers for radiation-induced acute intestinal symptoms (RIAISs) in cervical cancer patients by serum protein profiling. J Radiat Res. 2015 Jan;56(1):134-140

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572598/pdf/rru081.pdf

* Zhu L et al. (2014) Transthyretin as a novel candidate biomarker for preeclampsia. Exp Ther Med.7(5):1332-1336. Epub 2014 Feb 18

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991523/pdf/etm-07-05-1332.pdf

* Tsui H (2014) Neuropsychological and plasma biomarkers for detecting Alzheimer's disease. Brain Health Research Center.

• https://prezi.com/im4glafcxjra/neuropsychological-and-plasma-biomarkers/

* Hernandez C et al. (2013) Identification of new pathogenic candidates for diabetic macular edema using fluorescence-based difference gel electrophoresis analysis. Diabetes Metab Res Rev. 29(6):499-506.

• https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.2419

* Velayudhan L (2012) Clinical and biological markers of progression in Alzheimer?s disease. King's College London

• https://kclpure.kcl.ac.uk/portal/files/60841072/2013_Velayudhan_Latha_0546706_ethesis.pdf.

* Velayudhan L (2012) Plasma transthyretin as a candidate marker for Alzheimer's disease. J. Alzheimer?s Disease 28:369-375.

• https://content.iospress.com/download/journal-of-alzheimers-disease/jad110611?id=journal-of-alzheimers-disease/jad110611

* Velayudhan L et al. (2012) Plasma Transthyretin as a Candidate Marker for Alzheimer?s Disease.PLoS One. 7(6):e38703.

• http://genseq.molgen.mpg.de/cms/uploads/ADAMS%20publications/62_Velayudhan_2011.pdf

* Craig-Schapiro R (2012) Identification of Novel Fluid Biomarkers for Alzheimer's Disease. Washington University in St. Louis.

• https://openscholarship.wustl.edu/cgi/viewcontent.cgi?referer=https://scholar.google.com/&httpsredir=1&article=1684&context=etd

* Alvarez R et al. (2012) Compositions and methods for inhibiting expression of transthyretin. Patent number: US8168775 B2

• https://www.google.com/patents/US8168775?dq=Compositions+and+methods+for+inhibiting+expression+of+transthyretin.++Patent+number:+US8168775+B2&hl=en&sa=X&ei=bW5BVeLNDYaEsAXA1oCgCw&ved=0CB8Q6AEwAA

* Wang F and Miller S (2011) Mir 204, mir 211, their anti-mirs, and therapeutic uses of same. USPTO Patent Applicaton 20110190378

• http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20110190378.PGNR.

* Sah D (2011) Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR). WIPO Patent Application US2010/055311

• http://www.sumobrain.com/patents/wipo/Lipid-formulated-compositions-methods-inhibiting/WO2011056883.html

* Perrin RJ et al. (2011) Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PloSOne Jan 12; 6(1):e16032

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020224/pdf/pone.0016032.pdf

* Mastricci AL et al. (2011) Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11-13 Weeks? Fetal Diagn Ther. 30(1):53-59

• http://fetalmedicine.com/synced/fmf/2011_alm_08.pdf

* Alvarez R et al. (2011) siRNA therapy for transthyretin (ttr) related ocular amyloidosis. Patent application: CA 2792291 A1

• http://www.freepatentsonline.com/y2017/0096663.html

* Wang FE et al (2010) MicroRNA-204/211 alters epithelial physiology. FASEB J. 24(5):1552-1571

• http://www.fasebj.org/content/24/5/1552.full.pdf+html

* Maheshwari A et al. (2009) Developmental changes in circulating IL-8/CXCL8 isoforms in neonates. Cytokine. 46(1):12-16

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757161/pdf/nihms93057.pdf

* Chiang HL et al. (2009) Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barr? syndrome and other neurological disorders. Clinica Chimica Acta. 405(1-2):143-147

• https://www.sciencedirect.com/science/article/abs/pii/S000989810900223X#!

* Escher N et al. (2007) Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides1. Neoplasia. 9(3): 254-259

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1838582/pdf/neo0903_0254.pdf